Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have earned a consensus recommendation of “Hold” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $20.75.
A number of equities analysts have recently commented on HALO shares. Barclays reaffirmed a “sell” rating and set a $17.00 target price on shares of Halozyme Therapeutics in a research report on Monday, August 12th. ValuEngine raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, June 27th. BidaskClub raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. Cantor Fitzgerald raised their target price on shares of Halozyme Therapeutics from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, July 1st. Finally, Zacks Investment Research raised shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating and set a $18.00 target price on the stock in a research report on Wednesday, August 7th.
Shares of NASDAQ:HALO traded up $0.43 during trading on Friday, reaching $16.28. 470,600 shares of the company were exchanged, compared to its average volume of 805,187. The firm has a market capitalization of $2.32 billion, a PE ratio of -29.07 and a beta of 1.76. The business’s fifty day simple moving average is $16.77 and its 200-day simple moving average is $16.37. Halozyme Therapeutics has a 12-month low of $13.24 and a 12-month high of $18.85. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.89 and a quick ratio of 2.57.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NumerixS Investment Technologies Inc boosted its stake in shares of Halozyme Therapeutics by 70.7% during the second quarter. NumerixS Investment Technologies Inc now owns 2,390 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 990 shares in the last quarter. Steward Partners Investment Advisory LLC acquired a new stake in Halozyme Therapeutics in the second quarter valued at approximately $49,000. Ladenburg Thalmann Financial Services Inc. boosted its stake in Halozyme Therapeutics by 25.2% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,800 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 967 shares in the last quarter. Quantamental Technologies LLC acquired a new stake in Halozyme Therapeutics in the second quarter valued at approximately $173,000. Finally, CWM Advisors LLC acquired a new stake in Halozyme Therapeutics in the second quarter valued at approximately $175,000. Hedge funds and other institutional investors own 80.55% of the company’s stock.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Recommended Story: What is an inverted yield curve?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.